MICU2

Across TCGA pan-cancer cohorts, MICU2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MICU2 data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MICU2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MICU2 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, LUAD, and PDAC are the cancer types where MICU2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	II,III,IV	1.000	0.869	.029	24	view →
LUAD	DFS	Tertile	II,III,IV	0.288	0.692	.002	11	view →
PDAC	OS	Median	III,IV	0.853	0.367	.003	11	view →
CCRCC	DFS	Quartile	III,IV	0.050	0.714	.038	3	view →
GBM	DFS	Tertile	All	0.821	0.489	.017	3	view →
HNSC	DFS	Median	III,IV	0.493	0.911	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MICU2–COAD (DFS)

Open the COAD breakdown →